Australian biotechnology company Prima BioMed Ltd is one of the world's leaders when it comes to cancer treatment. We focus on developing anti-cancer therapeutics based on the emerging technology of immunotherapy. Scientific research, product development and clinical trials are the essentials of what we call the cutting edge of the fight against cancer.
The company has 2 programs in place. The lead program, CVac™ has completed Phase IIa clinical trials and focuses on the development of an ex vivo immunotherapy for ovarian cancer.
Prima BioMed's technologies all result from research on the human immune system. In summary, the technology platforms behind the Product Pipeline are: Dendritic cell therapy, Monoclonal Antibodies.
CVac™ cell therapy is a new and groundbreaking technology for the treatment of cancer. It stimulates the production of immune cells, produced naturally in the body, that attack cancer cells.
To learn more about Prima Biomed please visit their website at: primabiomed.com.au.